Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report published on Sunday morning. The firm issued a sell rating on the stock.

Separately, Maxim Group cut their target price on Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, November 12th.

Moleculin Biotech Stock Down 27.9 %

Shares of NASDAQ MBRX opened at $0.51 on Friday. Moleculin Biotech has a 12-month low of $0.50 and a 12-month high of $10.35. The stock’s fifty day simple moving average is $1.80 and its two-hundred day simple moving average is $2.28.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.